Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

High dose extended-release potassium citrate wax matrix tablet

a potassium citrate and high-dose technology, applied in the direction of pill delivery, granular delivery, digestive system, etc., can solve the problem of reducing production cost, and achieve the effect of increasing production capacity, good friability, and poor friability

Active Publication Date: 2016-03-29
NOVEX SCI PTE LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes how to produce high dose extended-release potassium citrate tablets by using non-granulated potassium citrate instead of a portion of the melt- or heat-granulated potassium citrate. This change does not affect the stability or effectiveness of the tablets. Additionally, replacing a portion of the melt- or heat-granulated potassium citrate with non-granulated potassium citrate increases production capacity and reduces production costs.

Problems solved by technology

Further, because melt- or heat-granulation is the most difficult step of the production process, replacing a portion of the melt- or heat-granulated potassium citrate with non-granulated potassium citrate increases production capacity and reduces production cost.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 2

[0019]Three batches of 10-meq tablets were prepared by using the heat-granulation technique of PCT / PH2012 / 000013. Each batch is 100,000 tablets. The formulation is given in Table 5.

[0020]

TABLE 5Ingredientmg / tablet% w / wPotassium citrate•H2O108085Carnauba wax17714Magnesium stearate131

[0021]The procedure is as follows:[0022]1. The potassium citrate was comminuted in a Fitzmill D6, knives forward, using perforated screen mesh 8.[0023]2. The comminuted potassium citrate from #1 was mixed with carnauba wax in a sigma mixer for 20 minutes.[0024]3. The granule from #2 was comminuted in a Fitzmill D6, knives forward, using perforated screen mesh 12.[0025]4. The granule from #3 was heated in a jacketed sigma mixer, with continued mixing. Heating was continued until the temperature reached 70° C., which is below the melting point of carnauba wax.[0026]5. The granule from #4 was discharged into plastic drums and allowed to cool to room temperature.[0027]6. The cooled granule from #5 was comminu...

example 4

[0040]Three batches of 15-meq tablets were prepared by using the heat-granulation technique of PCT / PH2012 / 000013. Each batch is 67,000 tablets. The formulation in w / w percent is the same as Example 2, except that the tablet weight is 1.5× (1905 mg). The process of preparation is the same as Example 2 except that the granule was compressed into 22.5×9.3 mm elliptical tablets with hardness of 11-14 kp. Friability was less than 3% for the three batches. Dissolution was performed according to USP 35. The results are as follows:

[0041]

TABLE 12Lot 1 (dissolution, 12 units)TimeRangeAverage30 min 37.9-41.5%39.5%1 hour51.6-56.2%54.5%3 hour82.1-87.3%84.5%

[0042]

TABLE 13Lot 2 (dissolution, 12 units)TimeRangeAverage30 min 36.1-38.2%37.1%1 hour48.9-53.2%50.2%3 hour73.2-80.9%76.8%

[0043]

TABLE 14Lot 3 (dissolution, 12 units)TimeRangeAverage30 min 35.6-39.6%37.0%1 hour49.9-52.1%51.2%3 hour74.0-82.9%78.2%

[0044]Two of the three batches fail USP dissolution. Further, the average values for the 30 min and...

example 5

[0045]Three formulations of 15-meq tablets with varying concentrations of carnauba wax were prepared by using the heat-granulation technique of PCT / PH2012 / 000013. The formulations are given in Table 15:

[0046]

TABLE 1515-meq Tablets (mg / tablet)IngredientExample 5AExample 5BExample 5CPotassium citrate•H2O162016201620Carnauba wax223 (12%)182 (10%)133 (7.5%)Magnesium stearate 19 18 18

[0047]The Process of preparation is the same as Example 2. The granules were compressed into 22.5×9.3 mm elliptical tablets. The results are as follows:

[0048]

TABLE 16Example 5A (dissolution, 12 units)TimeRangeAverage30 min 39.3-43.8%40.2%1 hour53.2-57.7%54.6%3 hour85.1-87.4%86.7%

[0049]The tablet hardness was about 10 kp, and friability was less than 3%. Note that reducing the carnauba wax from 14% in Example 4 to 12% in Example 5A did not change the mean dissolution values for the 30 min and 1 hour time points significantly.

[0050]

TABLE 17Example 5B (dissolution, 12 units)TimeRangeAverage30 min 47.0-50.1%48.5...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
w/waaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a high dose extended-release potassium citrate tablet containing carnauba wax, which contains a first portion of melt- or heat-granulated carnauba wax and potassium citrate; and a second portion of non-granulated potassium citrate. The high dose extended-release potassium citrate tablet of this invention has robust batch-to-batch dissolution and friability; and leads to improved production capacity and reduced production cost.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a U.S. National Stage application under 35 U.S.C. §371 of International Application PCT / PH2013 / 000007 (published as WO 2014 / 133401 A1), filed Feb. 28, 2013. Benefit of the filing date of this application is hereby claimed. This application is hereby incorporated by reference in its entirety.BACKGROUND OF THE INVENTION[0002]Potassium citrate is used clinically to treat kidney stones by alkalizing the urinary pH and increasing urinary citrate concentration. However, its therapeutic efficacy is limited by its gastrointestinal complications such as irritation and ulcerations. Extended-release tablets of potassium citrate could minimize these side effects and have been shown to lead to sustained elevation of urinary pH and citrate concentration (Pak et al., 1984).[0003]Considerable difficulties have been encountered in the preparation of extended-release matrix tablets containing potassium citrate. Potassium citrate is very...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): A61K9/16A61K9/20A61K31/194
CPCA61K31/194A61K9/2013A61K9/2077A61K9/2095A61P1/04A61P13/02A61P13/04A61P13/12A61P29/00
Inventor MENDOZA, WENDELL, G.SANTOS, RITA, JOSEFINA, M.DEE, KENNIE, U.
Owner NOVEX SCI PTE LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com